AADI - Aadi Bioscience, Inc. Stock Price, Fair Value and News

$2.08-0.02 (-0.95%)

Delayed as of 22 Oct 2024, 09:41 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

AADI Price Action

Last 7 days

-2.3%

Last 30 days

8.8%

Last 90 days

33.8%

Trailing 12 Months

-48.7%

AADI RSI Chart

AADI Valuation

Market Cap

51.7M

Price/Earnings (Trailing)

-0.79

Price/Sales (Trailing)

2.17

EV/EBITDA

0.12

Price/Free Cashflow

-0.96

AADI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AADI Fundamentals

AADI Revenue

Revenue (TTM)

23.8M

Rev. Growth (Yr)

-0.37%

Rev. Growth (Qtr)

15.43%

AADI Earnings

Earnings (TTM)

-65.4M

Earnings Growth (Yr)

18.85%

Earnings Growth (Qtr)

20.26%

AADI Profitability

EBT Margin

-270.66%

Return on Equity

-83.06%

Return on Assets

-64.4%

Free Cashflow Yield

-103.69%

AADI Investor Care

Shares Dilution (1Y)

0.39%

Diluted EPS (TTM)

-2.42

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	23.8M	23.8M	0	0
2023	18.8M	21.5M	23.3M	24.4M
2022	14.3M	14.6M	14.9M	15.2M
2021	14.0M	14.0M	14.0M	14.0M
2020	18.6M	17.1M	15.5M	14.0M
2018	0	6.8M	13.5M	20.2M
2017	158.3K	88.6K	108.8K	93.7K
2016	310.1K	250.5K	190.9K	131.3K
2015	0	0	0	369.7K

Get all data in R, Python etc through our Historical Stock Data APIs

About Aadi Bioscience, Inc.

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus bound to albumin. The company is also involved in evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

CEO	Mr. Scott M. Giacobello CPA
WEBSITE	https://aadibio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	89

Aadi Bioscience, Inc. Frequently Asked Questions

What is the ticker symbol for Aadi Bioscience, Inc.? What does AADI stand for in stocks?

AADI is the stock ticker symbol of Aadi Bioscience, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aadi Bioscience, Inc. (AADI)?

As of Mon Oct 21 2024, market cap of Aadi Bioscience, Inc. is 51.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AADI stock?

You can check AADI's fair value in chart for subscribers.

Is Aadi Bioscience, Inc. a good stock to buy?

The fair value guage provides a quick view whether AADI is over valued or under valued. Whether Aadi Bioscience, Inc. is cheap or expensive depends on the assumptions which impact Aadi Bioscience, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AADI.

What is Aadi Bioscience, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Oct 21 2024, AADI's PE ratio (Price to Earnings) is -0.79 and Price to Sales (PS) ratio is 2.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AADI PE ratio will change depending on the future growth rate expectations of investors.